By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CombiMatrix said after the close of the market Thursday that its board of directors has authorized management of the firm to voluntarily apply to have its stock transferred to the Nasdaq Capital Market from the Nasdaq Global Market.

The firm has decided to take this action rather than submit a plan to the exchange to regain compliance with Nasdaq Global Market listing requirements.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

ScienceInsider reports that a new security policy at the US Food and Drug Administration may prevent foreign nationals from working there.

WBUR in Boston looks into Orig3n's genetic fitness assessments to find more research is needed.

Cleveland.com reports that getting a DNA profile removed from a law enforcement database can be tricky.

In PNAS this week: de novo mutations contribute to non-syndromic craniosynostosis, fungal tree of life, and more.